Introduction
Inflammatory bowel disease (IBD) is an idiopathic, chronic, and frequently disabling inflammatory disorder of the intestine that has two subtypes: Crohn's disease (CD) and ulcerative colitis (UC), each accounting for approximately 50% of IBD patients (1) (2) (3) . In the United States alone, there are 1.4 million diagnosed IBD patients. It is clear that IBD is a complex multifactorial disease with both genetic and environmental contributions (1) (2) (3) (4) , yet the precise etiology of the mucosal dysregulation remains elusive (4) . Despite the therapeutic options available for the management of IBD, approximately one-third of IBD patients do not respond to any given therapy, and there is no cure (5) . This emphasizes the significance of exploring and identifying novel therapies for patients with IBD.
A novel therapeutic approach was recently suggested by the finding that the expression of the FOLH1 gene is dramatically increased in IBD (6) (7) (8) . Using an unbiased statistical analysis of genome-wide expression data from biopsy samples, the FOLH1 gene was identified as a "hub" gene, with significant correlations to over a dozen known IBD gene biomarkers. Immunohistochemical staining confirmed the elevated expression of the FOLH1 protein in the villous epithelium of samples from patients when compared with non-IBD controls. These findings suggest that FOLH1 might serve as a biomarker for disease and could serve as a possible therapeutic target.
FOLH1 encodes a transmembrane glycoprotein that acts as a glutamate carboxypeptidase. In the intestines, the enzyme is called folate hydrolase and is found on brush border membranes where it is involved in Recent gene-profiling analyses showed significant upregulation of the folate hydrolase (FOLH1) gene in the affected intestinal mucosa of patients with inflammatory bowel disease (IBD). The FOLH1 gene encodes a type II transmembrane glycoprotein termed glutamate carboxypeptidase II (GCPII). To establish that the previously reported increased gene expression was functional, we quantified the glutamate carboxypeptidase enzymatic activity in 31 surgical specimens and report a robust 2.8-to 41-fold increase in enzymatic activity in the affected intestinal mucosa of IBD patients compared with an uninvolved area in the same patients or intestinal mucosa from healthy controls. Using a human-to-mouse approach, we next showed a similar enzymatic increase in two well-validated IBD murine models and evaluated the therapeutic effect of the potent FOLH1/ GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) (IC 50 = 300 pM). In the dextran sodium sulfate (DSS) colitis model, 2-PMPA inhibited the GCPII activity in the colonic mucosa by over 90% and substantially reduced the disease activity. The significance of the target was confirmed in FOLH1 -/-mice who exhibited resistance to DSS treatment. In the murine IL-10 -/-model of spontaneous colitis, daily 2-PMPA treatment also significantly reduced both macroscopic and microscopic disease severity. These results provide the first evidence of FOLH1/GCPII enzymatic inhibition as a therapeutic option for IBD.
the sequential cleavage of terminal γ-linked glutamate residues from dietary polyglutamyl folates to enable the absorption of folate. In addition to the gut, the enzyme is also highly expressed in prostate cancer and in the neovasculature of solid tumors, in which it is termed prostate-specific membrane antigen (PSMA) and serves as a cancer biomarker (9) (10) (11) . In the brain and peripheral nervous system, in which it cleaves the abundant dipeptide neurotransmitter N-acetylaspartylglutamate (NAAG) to liberate glutamate (12, 13) , the enzyme is referred to as glutamate carboxypeptidase II (GCPII). Multiple classes of potent and selective small-molecule GCPII inhibitors have been synthesized (14) (15) (16) (17) (18) and shown to have profound therapeutic effects in a variety of preclinical models of neurological disorders wherein excess glutamate is implicated (18) (19) (20) (21) (22) .
Herein, we report that the previously described increased FOLH1 gene expression results in a large and significant increase of glutamate carboxypeptidase activity selectively in the affected intestinal mucosa of patients with both active CD and UC. In addition, a similar degree of increase in enzymatic activity was detected in preclinical models of colitis. Given the correlation in human and IBD preclinical models, we next evaluated the effect of pharmacological inhibition of FOLH1/GCPII using the potent and selective inhibitor 2-PMPA. We demonstrate that systemic administration of 2-PMPA blocks the colonic glutamate carboxypeptidase activity and ameliorates IBD symptoms in two widely used murine preclinical models. Last, we validated FOLH1/GCPII as a therapeutic target by showing that FOLH1 -/-mice are significantly protected against experimental colitis.
Results
Increased FOLH1/GCPII enzymatic activity in IBD patients. FOLH1/GCPII enzymatic activity was evaluated in 31 surgical specimens from 20 subjects with either CD or UC or from normal controls. When comparing to normal colon from healthy volunteers, the enzymatic activity was robustly increased in diseased colon from both UC (3.6 ± 1.2-fold; P < 0.05) and CD (3.04 ± 0.73-fold; P < 0.01) subjects. An even larger increase in enzymatic activity was observed in diseased ileum tissue (8.6 ± 3.5-fold; P < 0.01) ( Figure 1A ). When comparing FOLH1/GCPII activity in diseased versus uninvolved intestinal mucosa specimens from the same patients, we observed a robust 2.8-to 41-fold increase associated with disease ( Figure 1B) .
Increased FOLH1/GCPII enzymatic activity in murine models of colitis. FOLH1/GCPII enzymatic activity was evaluated in the colon and ileum of dextran sodium sulfate-treated (DSS-treated) and IL-10 -/-mice and compared with vehicle-treated and WT mice, respectively. DSS-treated mice (2.5 % w/v for 7 days) had significantly Figure 1 . Elevation of FOLH1/glutamate carboxypeptidase II activity in the diseased intestinal mucosa of patients with IBD. FOLH1/glutamate carboxypeptidase II (FOLH1/GCPII) enzymatic activity was measured in involved (inflamed with active disease) and uninvolved (macroscopically normal) mucosal specimens from IBD patients or from non-IBD controls. (A) Significant enhancement of GCPII activity was observed in diseased mucosal specimens taken from Crohn's disease (CD) and ulcerative colitis (UC) patients when compared with specimens from normal healthy controls in both colon and ileum. Data are shown as mean ± SEM (n = 31 samples) (*P < 0.05, **P < 0.01, 2-tailed t test). (B) Within the same IBD patient, a robust increase in enzymatic activity was observed in the diseased intestinal mucosa specimens when compared with that in an uninvolved region from the same patient. Data are presented as individual specimens (n = 19). The Arabic numbers refer to different patients. The pound sign indicates that an uninvolved normal region from this patient was not available.
enhanced enzymatic activity versus vehicle-treated mice in the colon (1.5 ± 0.3-fold; P < 0.05; Figure 2A) , with a trend towards an increase in the ileum (1.4 ± 0.2-fold; NS; Figure 2A ). Similarly, FOLH1/GCPII enzymatic activity was also significantly elevated in the inflamed colonic mucosa of 12-to 16-week-old IL-10 -/-mice when compared with similarly aged WT mice (3.9 ± 0.7-fold versus WT; P < 0.0001; Figure  2B ). Ileal tissues of IL-10 -/-mice also displayed significant enzymatic activity increases (2.30 ± 0.29-fold versus WT; P < 0.0001; Figure 2B ).
FOLH1/GCPII inhibitor 2-PMPA ameliorates disease activity in the DSS model of colitis. Daily 2-PMPA (100 mg/kg i.p.) administration in DSS-treated mice resulted in significantly decreased disease activity index (DAI) scores following 5 days of treatment, based on improved body weight, better stool consistency, and reduced rectal bleeding (P < 0.01; Figure 3A ). To confirm FOLH1/GCPII target engagement, we evaluated both the 2-PMPA drug levels and FOLH1/GCPII inhibitory activity in intestinal samples from DSS-treated mice. FOLH1/GCPII enzymatic activity was >90% reduced in 2-PMPA-treated mice, indicating clear target engagement (P < 0.001; Figure 3B ). 2-PMPA drug levels were 23.0 ± 1.4 nmol/ml in plasma and 21.4 ± 1.2 nmol/g in the colonic mucosa at 2 hours following 100 mg/kg i.p. dosing, exceeding the drug's IC 50 for FOLH1/GCPII (23) . These data provide strong support for FOLH1/GCPII target engagement and functional inhibition during the efficacy experiments. Histologically, vehicle-treated mice exhibited more severe mucosal damage, including diminished goblet cells, loss or distorted crypts, neutrophil infiltration, and marked thickening of the muscularis mucosa, submucosa, and muscularis propria, when compared with 2-PMPA-treated mice ( Figure 3C ).
FOLH1 -/-mice are resistant to DSS-induced colitis. FOLH1
-/-mice treated with DSS consistently exhibited a lower mean DAI score than their age-matched WT controls (P < 0.05; Figure 4A ). Mean colon length was also significantly longer in FOLH1 -/-mice versus WT controls (P < 0.01; Figure 4B ), suggesting less overall inflammation. Histologically, while WT mice exhibited massive neutrophil infiltration and loss of crypts and goblet cells, FOLH1 -/-mice showed healthier colonic mucosa, with noticeably less neutrophil infiltration and better-preserved crypts and goblet cells ( Figure 4C ).
FOLH1/GCPII inhibitor 2-PMPA ameliorates spontaneous colitis in the IL-10 -/-model. As described previously (24), IL-10 -/-mice spontaneously develop colitis that is characterized by a hypertrophic colon and development of rectal prolapse starting at approximately 3 to 4 months of age. In this study, daily treatment with 2-PMPA (100 mg/kg i.p.) was initiated in 16-to 18-week-old IL-10 -/-mice and continued daily for 3 weeks. No change in overall body weight was observed between the groups. However, at sacrifice 2-PMPA-treated mice exhibited significantly less colonic hypertrophy as indicated by a significant decrease in the colon weight (0.49 ± 0.06 g vs. 0.64 ± 0.07 g; P < 0.001; Figure 5B ), better stool consistency ( Figure 5A ), and, Figure 2 . Elevation of FOLH1/GCPII activity in murine models of colitis. FOLH1/glutamate carboxypeptidase II (FOLH1/ GCPII) enzymatic activity was evaluated in colon and ileum samples from two well-validated preclinical models of IBD. (A) Dextran sodium sulfate-treated (DSS-treated) mice showed significant enhancement of FOLH1/GCPII activity versus vehicle-treated mice in colon; a similar trend was observed in the ileum samples, although statistical significance was not achieved (*P < 0.05, 2-tailed t test). (B) IL-10 -/-mice showed a statistically significant enhancement of FOLH1/ GCPII activity in both inflamed colon and ileum samples versus WT mice. Data are shown as mean ± SEM. Mouse samples (n = 4-7 for each group) were analyzed and assays were performed in triplicate (***P < 0.0001, 2-tailed t test).
in some cases (2 of 10), even prolapse retraction (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/jci.insight.88634DS1). H&E staining from the intestines demonstrated remarkably improved histology, including less hypertrophic mucosa, fewer infiltrating neutrophils, and preserved crypts and goblet cells ( Figure 5C ).
Discussion
The experiments reported here demonstrate, for the first time, the potential therapeutic effects of FOLH1/ GCPII inhibition in IBD. Increased FOLH1 gene expression was recently reported in biopsy tissue extracted from IBD patients, specifically ileal CD samples (6, 8) . In fact, the gene was described as a ''hub'' gene, with significant correlations to 12 of 16 other IBD gene biomarkers (6) . These correlations suggested that the gene product of FOLH1, a type II transmembrane glycoprotein termed GCPII (EC 3.4.17.21), might serve not only as an IBD biomarker, but also as a therapeutic target.
We found that relative to non-IBD subjects, the FOLH1/GCPII enzymatic activity was robustly and significantly increased in diseased ileum and colon from both UC and CD subjects. In agreement with the FOLH1 gene expression profile, the largest mean increase (8.6-fold) was seen in ileal CD patients. In addition, the enzymatic activity clearly differentiated diseased versus uninvolved areas within each patient, with increases ranging from 2.8 to 41-fold. These results demonstrate that the previously reported increase in FOLH1 gene expression (6-8) is associated with increased functional enzymatic activity and is specific for areas affected by disease (see Figure 1) . Given that FOLH1/GCPII activity assays are well reduced colitis severity as indicated by the reduced disease activity index (DAI) scores which is a composite score of body weight, stool consistency, diarrhea and intestinal/rectal bleeding. Data are shown as mean ± SEM (n = 20 mice per group) (**P < 0.01, ***P < 0.001, 2-tailed t test). (B) 2-PMPA inhibits FOLH1/GCPII enzymatic activity in colonic mucosal extracts from dextran sodium sulfate-treated (DSS-treated) mice by > 90% confirming target engagement. Mouse samples (n = 4) were analyzed per group and assays were performed in triplicate. (***P < 0.001, 2-tailed t test). (C) Representative images of H&E-stained colon sections of 2-PMPA-and vehicle-treated mice with DSS-induced colitis (n = 5 per group). Untreated mice exhibited severe colitis, with disrupted epithelial linings, loss of crypts, thickening of the bowel wall, and massive infiltration of the inflammatory cells. 2-PMPA treatment led to protection of the crypts and drastic reduction of the inflammatory cell infiltration. Original magnification, ×100. M, mucosal layer; SM, submucosal; ML, muscular layer validated and simple to conduct (25) , they could be developed as an alternative to current histological methods for IBD diagnosis.
Given the profoundly increased enzymatic activity within diseased areas in patients, we next determined if a similar increase in enzymatic activity occurred in preclinical IBD models. Using the widely employed DSS and IL-10 -/-murine models of colitis, we showed a significant increase in FOLH1/GCPII activity in the colons of diseased versus vehicle-treated or WT mice, respectively. A similar significant increase in enzymatic activity was observed in the ileum samples of IL-10 -/-mice versus WT mice, while, in DSS mice, an increasing trend versus vehicle-treated mice was observed, but it did not reach significance. The recapitulation of the increased enzymatic activity in a mouse model prompted us to evaluate the therapeutic effect of enzyme inhibition in the mouse IBD model. Systemic administration of the potent and selective FOLH1/GCPII inhibitor, 2-PMPA (23, 26) , was found to dramatically ameliorate IBD symptoms in the IL10 -/-model, a finding which was reproduced in DSS-induced colitis. Specifically, 2-PMPA significantly decreased disease severity as measured by disease activity index, colon length, colon weight, stool consistency, and/or histopathology. The drug effect was particularly remarkable in the IL10 -/-mice, in which 2-PMPA treatment resulted in a retraction of prolapse in 2 of the 10 mice exhibiting prolapse prior to treatment, a phenomenon that we have not previously observed in our laboratory. This improvement was unequivocal in that the body weight of these prolapse-retracting mice also increased dramatically while the colon weight markedly decreased (healthier colon) (Supplemental Figure 1) . We subsequently confirmed that these beneficial effects were due to FOLH1/GCPII inhibition. First, we demonstrated that following systemic administration, the 2-PMPA concentration in the colonic mucosa exceeded the drug's IC 50 and resulted in a >90% decrease in FOLH1/GCPII enzymatic activity. In addition to the pharmacokinetic/ pharmacologic evidence of target engagement, the role of GCPII was further confirmed in FOLH1 -/-mice, as they were found to be significantly protected from DSS-induced colitis when compared with WT mice. -/-and WT mice were given dextran sodium sulfate (DSS) in their drinking water for 7 days, and disease activity index (DAI) was monitored daily.
Data are shown as mean ± SEM (n = 14 mice/group). (A) FOLH1
-/-mice showed significantly reduced DAI compared with WT mice (**P < 0.01, ***P < 0.
001, 2-way ANOVA). (B) FOLH1
-/-mice showed significantly longer colons compared with WT, suggesting reduced inflammation (n = 5-14 mice per group) (***P < 0.
001, 2-tailed t test). (C) Histological evaluation confirmed that FOLH1
-/-mice exhibited markedly reduced disease in response to DSS (n = 5 per group). WT mice exhibited thickening of the colon wall, including mucosa and muscular layers, as well as massive leukocyte infiltration, loss of crypts, and diminishing goblet cells, while the FOLH1 -/-mice showed relatively minor changes, with clearly defined crypts and visible goblet cells, as well as drastically reduced number of inflammatory cell infiltration. Original magnification, ×100. M, mucosal layer; SM, submucosal; ML, muscular layer.
While the efficacy of FOLH1/GCPII inhibition in IBD preclinical models is clear, the site of action and therapeutic mechanism has yet to be determined. With regard to site of action, although the increased expression in IBD patients has been reported in epithelial cells (6) it is also possible that inhibition of FOLH1/ GCPII may affect the enteric nervous system or infiltrating immune cells. Of interest, our laboratory recently found that GCPII is highly upregulated in microglial cells (e.g., the immune cells of the brain) following inflammation and its inhibition prevents neurological damage (27) . With respect to enzymatic mechanism, to date there are 3 known FOLH1/GCPII substrates that could be implicated as possible mediators of the therapeutic effect, including N-acetylaspartylglutamate (NAAG) (28), folate polyglutamate (29-31), and laminin-derived peptides (32, 33) . NAAG is one of the most abundant peptides in nervous tissues where it is thought to participate in glutamatergic transmission, acting through NMDA and mGlu3 receptors (20, 34, 35) . Although little is known about NAAG in the enteric nervous system, its receptors have been reported in the gut (36) . Similar to FOLH1/GCPII upregulation in IBD, increased enzyme activity has been reported in a variety of nervous system diseases (36) (37) (38) (39) (40) (41) (42) , including neuroinflammation (36, (41) (42) (43) (44) . In order to determine the role of NAAG and its receptors in IBD, more detailed studies on NAAG localization, synthesis, and regulation under both normal conditions and in IBD are required. It would also be of interest to examine the effects of agonists and antagonists of these receptors on disease. A second known substrate is folate poly-γ-glutamate. The enzyme is responsible for sequential removal of the multiple terminal γ-linked glutamates to generate folic acid, which is actively absorbed by the reduced folate carrier. It is possible that elevated folate hydrolase activity in IBD provides improved folate availability from the gut to support nucleotide biosynthesis and cell division of inflammatory cells. In support of this possibility, antifolate drugs such as methotrexate are an effective IBD treatment (45) . Finally, there is a possible antiangiogenic effect of FOLH1/ GCPII inhibition in IBD. The enzyme has been hypothesized to be a proangiogenic surface protease, which (C) Histological evaluation showed that 2-PMPA treatment led to a healthier colon. Untreated mice exhibited marked thickening of the colon wall as a result of excessive hyperplasia, massive leukocyte infiltration, loss of crypts, and diminishing of goblet cells, while the 2-PMPA-treated group showed relatively minor changes. Original magnification, ×100. M, mucosal layer; SM, submucosal; ML, muscular layer.
is highly upregulated in the neovasculature of solid tumors (10, 33, 46, 47) . FOLH1/GCPII is thought to hydrolyze laminin peptides to liberate fragments that enhance endothelial cell adhesion and migration (32) . Importantly, enhanced angiogenesis has been a characteristic feature of both CD and UC (48, 49) , and angiogenesis blockade has been shown to effectively ameliorate experimental colitis (50) (51) (52) . Our laboratory has recently identified a specific angiogenic dipeptide derived from GCPII cleavage of laminin (53) and plans to explore its regulation in IBD with/without GCPII treatment. In summary, we have used a human-to-mouse strategy and translated an unexpected finding in a human IBD GWAS study to identify a therapeutic approach. Specifically, we have demonstrated a large and significant increase of glutamate carboxypeptidase activity in clinical biopsy samples from disease-affected areas compared with unaffected areas in both CD and UC. We then moved to animal models showing a similar enzymatic increase associated with disease. Subsequently, we showed that systemic administration of a potent and selective FOLH1/ GCPII inhibitor could ameliorate IBD symptoms and that FOLH1 -/-mice are resistant to disease. We are currently working to identify the relevant substrates and receptors affected by FOLH1/GCPII inhibition in the gut, which may lead to additional therapeutic targets. While further mechanistic studies are underway, the present data strongly support the utility of FOLH1/GCPII as both a biomarker and therapeutic target in IBD. Our findings lay the foundation for rapid development and clinical translation of FOLH1/GCPII inhibitors for the treatment of IBD.
Methods
2-PMPA was synthesized by our laboratory using methods reported previously (23) . LC/MS-grade acetonitrile and water with 0.1% formic acid were obtained from Fisher Scientific. DSS was obtained from Affymetrix, and heparinized rat plasma was obtained from Innovative Research Inc. All other chemical and reagents were purchased from Sigma-Aldrich.
FOLH1/GCPII enzymatic activity in patient samples. Surgically resected intestinal mucosa from patients with CD and UC and non-IBD subjects were donated by the Johns Hopkins Gastroenterology Department (Baltimore, Maryland, USA). Tissue samples (intestinal mucosa), from both involved (diseased) and uninvolved (no disease) colon or ileum of IBD patients or normal intestine of healthy controls, were obtained from surgically resected intestine or endoscopic biopsies and stored immediately in liquid nitrogen. Glutamate carboxypeptidase activity in the samples was measured using a previously described radioenzymatic assay by our laboratory (54, 55) . In brief, intestinal tissues were weighed and immersed in 0.5 ml of ice-cold 50 mM Tris buffer (pH 7.7 at room temperature). Each tissue was sonicated for 30 to 60 seconds using an ultrasonic cell disrupter. After a 2 minute spin at 13,000 g, supernatants were analyzed for protein content and glutamate carboxypeptidase activity.
DSS murine model of colitis. Six-to eight-week-old adult male C57BL/6 mice were obtained from Jackson Laboratories. The animals were housed in the Johns Hopkins animal facility under controlled temperature (25°C) and photoperiods (12-hour-light/12-hour-dark cycle) with access to standard diet and water (or specified DSS-containing drinking water) ad libitum. Mice were housed 5 per cage and allowed to acclimate to these conditions for at least 7 to 10 days before inclusion in experiments.
For the functional enzymatic activity assessment, mice were randomized before the start of the DSS treatment on the basis of body weight and age into two equivalent experimental groups (n = 5/group), including vehicle and DSS plus vehicle. Acute colitis was induced by administration of 2.5% (w/v) DSS (MW 40,000-50,000) in the drinking water for 7 days as described previously (56, 57) . On day 8, the colon and ileum were removed and feces were flushed clean with cold saline using a syringe and weighed. Glutamate carboxypeptidase activity was then measured in the samples using our previously described radioenzymatic assay (54, 55) , which is detailed above.
For the efficacy studies, mice (n = 20 per group) were similarly randomized before the start of the DSS treatment on the basis of body weight and age into three equivalent experimental groups: (a) vehicle, (b) DSS plus vehicle, and (c) DSS plus 2-PMPA. Acute colitis was induced by administration of 2.5% (w/v) DSS (MW 40,000-50,000) in the drinking water for 7 days. Daily dosing of i.p. vehicle (HBSS) or 2-PMPA (100 mg/kg) began when DSS was initiated and was continued until sacrifice on day 8. Disease status was monitored using a DAI, including body weight, stool consistency, diarrhea, and intestinal/rectal bleeding, based on well-established scores that simulate clinical IBD presentations (58) . Specifically, the following criteria were used: (a) weight loss (0 = none; 1 = 1%-5% loss; 2 = 5%-10% loss; 3 = 10%-15% loss; 4 = more than 15% loss); (b) stool consistency (0 = normal; 1 = slightly soft; 2 = soft but still formed; 3 = soft and not formed; 4 = watery diarrhea); and (c) bleeding (0 = negative; 1 = blood test +; 2 = blood test ++; 3 = visible blood trace in stool; 4 = rectal bleeding), as assessed by the ColoScreen occult blood test (Helena Laboratories). For the knockout mouse studies, FOLH1 -/-mice were provided by Joseph Neale (Georgetown University, Washington, DC, USA), who had received them originally from Warren Heston (Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA) (59). The mice had been backcrossed at least 10 times to C57BL/6. For this study, male FOLH1 -/-mice and C57BL/6J WT mice (6-8 weeks old) were given 2.5% DSS w/v in their drinking water for 7 days, and their DAI was monitored as detailed above.
IL-10 -/-murine model of spontaneous colitis. C57BL/6 IL-10 -/-, 6-to 8-week-old, 18-22 g mice were obtained from Jackson Laboratories. Animals were housed under specific pathogen-free conditions at the Johns Hopkins animal facility for approximately 10 weeks before the beginning of the experiment to allow spontaneous disease onset.
For the functional enzymatic assay assessments, 12-to 16-week-old IL-10 -/-and age-matched WT mice were used. Colon and ileum were removed, feces were flushed, intestinal samples were weighed, and glutamate carboxypeptidase activity in the samples was measured using a radioenzymatic assay previously described by our laboratory (54, 55) and detailed above.
For the efficacy studies, 16-to 18-week-old IL-10 -/-mice were divided to 2 groups (with 18-20 mice per group) and given daily i.p. injection of vehicle (HBSS) or 100 mg/kg 2-PMPA for 3 weeks before sacrifice. Body weight and rectal prolapse were measured and recorded daily. Following sacrifice, the abdomen of the mice was opened by a ventral midline incision. The colon was removed and feces were flushed clean with cold saline using a syringe. Colon weight, length, and stool consistency were then determined as we have previously described (57) .
Histological evaluation. Five-mm segments of proximal and distal colon were resected and fixed in 10% neutral buffered formalin for histological examination as described previously (57) . Briefly, tissues were embedded in paraffin wax, sectioned into 4-μm-thick sections with a paraffin microtome (ThermoFisher), and mounted on microscope slides (Fisher Scientific). Dewaxed sections were stained with H&E (Richard Alen Scientific). Histological images were obtained using a Zeiss Axio Observer microscope with an Olympus DP72 camera (Zeiss).
FOLH1 target engagement studies. To confirm that 2-PMPA was engaging and inhibiting the FOLH1/ GCPII enzyme, glutamate carboxypeptidase enzymatic activity measurements in colonic mucosa were assessed in mice at the end of the efficacy studies at 2 hour following the last 2-PMPA dose. Tissues were weighed and immersed in 0.5 ml of ice-cold 50 mM Tris buffer (pH 7.7 at room temperature). While on ice, each tissue was sonicated for 30 to 60 seconds (medium output, 60) using a Kontes ultrasonic cell disrupter. After a 2 minute spin at 13,000 g, supernatants were analyzed for protein content (DC Protein Assay Kit; Bio-Rad) and glutamate carboxypeptidase activity as per our published procedures (54, 55) .
2-PMPA analysis in plasma and colon. Two hours following the last 2-PMPA dose in the DSS efficacy studies, mice were anesthetized in a chamber containing isoflurane and then sacrificed by cervical dislocation, and blood and colonic mucosa were collected for 2-PMPA bioanalysis. Plasma was generated from blood by centrifugation, and samples were stored at -80°C until bioanalysis. Concentrations of 2-PMPA in plasma and colon mucosa were determined via LC/MS/MS, as we have previously described (60) . Briefly, 2-PMPA was extracted from plasma and tissue by protein precipitation with 6X methanol containing 2-(phosphonomethyl) succinic acid (2-PMSA; 1 μM) as an internal standard. The samples were vortexed (30 s) and centrifuged (10,000 g for 10 min). Supernatants were dried under a gentle stream of nitrogen at 45°C and the residue reconstituted with 100 μl of acetonitrile. 50 μl of the derivatizing agent N-tert-Butyldimethysilyl-N-methyltrifluoro-acetamide (MTBSTFA) was added, and samples were heated at approximately 60°C for 40 minutes. At the end of 40 minutes, the derivatized samples were analyzed via LC/MS/MS. Chromatographic analysis was performed using an Accela ultra high-performance system consisting of an analytical pump and an autosampler coupled with TSQ Vantage mass spectrometer (Thermo Fisher Scientific Inc.).
Statistics. All data, except for that shown in Figure 1B , is presented as mean ± SEM. Statistical analyses were performed using Graph Pad Prism 6.0. Comparisons between groups in human and animal studies were made with 2-tailed t tests. Evaluation of differences in disease activity indices was performed with 2-way ANOVA. P values of less than 0.05 were considered statistically significant for all data.
Study approval. Surgically resected intestinal mucosa from patients with CD and UC and non-IBD subjects were donated by the Johns Hopkins Gastroenterology Department. Specimen collection was approved by the Johns Hopkins University Review Board (NA00038329/CR00009103), and the diagnosis was based on the pathology report issued by a well-trained pathologist assigned to each respective case. All patients signed a written consent form to participate. The experimental protocol (MO16M13) for murine IBD studies was approved by the Institutional Animal Care and Use Committee of Johns Hopkins University and adhered to all of the applicable institutional and governmental guidelines for the humane treatment of laboratory animals.
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